Trends in GLP ‐1 Receptor Agonist Prescribing Without an Apparent FDA ‐Approved Indication

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns2025 · 53 citations
2. 2Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities2025 · 1 citations
3. 3Abstract TH822: Characteristics of Glucagon-like Peptide-1 Receptor Agonist Initiators and Temporal Trends in Prescriptions by Diabetes Status; MarketScan 2016-20232026
4. 4Trends in Glucagon-Like Peptide-1 Agonist Use and BMI Among Obese Adults With Type 2 Diabetes: Analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), Adjusted for Cardiovascular Comorbidity.2025 · 1 citations
5. 51438-P: Trends in Obesity and GLP-1RA Use among Youth and Adults with Type 1 Diabetes in U.S. Health System—2008–20222024